share_log

This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

這位Kohl's分析師不再看好;以下是星期一的五大評級下調。
Benzinga ·  12/02 09:05

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

華爾街頂級分析師改變了對這些頂級公司的展望。如需查看包括升級和降級在內的所有分析師評級變化的完整視圖,請參閱我們的分析師評級頁面。

  • Morgan Stanley analyst Patrick Wood downgraded the rating for Glaukos Corporation (NYSE:GKOS) from Equal-Weight to Underweight and announced a $120 price target. Glaukos shares closed at $143.65 on Friday. See how other analysts view this stock.
  • TD Cowen analyst Andrew Kligerman downgraded Markel Group Inc. (NYSE:MKL) from Buy to Hold and lowered the price target from $1,986 to $1,836. Markel Group shares closed at $1,782.92 on Friday. See how other analysts view this stock.
  • Guggenheim analyst Robert Drbul downgraded the rating for Kohl's Corporation (NYSE:KSS) from Buy to Neutral. Kohl's shares closed at $14.97 on Friday. See how other analysts view this stock.
  • Goldman Sachs analyst Will Nance downgraded Toast, Inc (NYSE:TOST) from Buy to Neutral but raised the price target from $34 to $45. Toast shares closed at $43.54 on Friday. See how other analysts view this stock.
  • Chardan Capital analyst Daniil Gataulin downgraded Outlook Therapeutics, Inc. (NASDAQ:OTLK) from Buy to Neutral. Outlook Therapeutics shares closed at $2.05 on Friday. See how other analysts view this stock.
  • 摩根士丹利分析師Patrick Wood將Glaukos公司(紐交所:GKOS)的評級從等權降級爲低按金,並宣佈目標價爲120美元。 Glaukos股價週五收於143.65美元。看看其他分析師如何看待這隻股票。
  • TD Cowen分析師Andrew Kligerman將Markel Group公司(紐交所:MKL)的評級從買入調整爲持有,將目標價從1,986美元降至1,836美元。 Markel Group股價週五收於1,782.92美元。看看其他分析師如何看待這隻股票。
  • 古根海姆分析師Robert Drbul將Kohl's公司(紐交所:KSS)的評級從買入調降爲中立。 Kohl's股價週五收於14.97美元。看看其他分析師如何看待這隻股票。
  • 高盛分析師Will Nance將Toast, Inc(紐交所:TOST)的評級從買入調整爲中立,但將目標價從34美元提高至45美元。 Toast股價週五收於43.54美元。看看其他分析師如何看待這隻股票。
  • Chardan Capital分析師Daniil Gataulin將Outlook Therapeutics, Inc(納斯達克:OTLK)的評級從買入調降爲中立。 Outlook Therapeutics股價週五收於2.05美元。看看其他分析師如何看待這隻股票。

Considering buying KSS stock? Here's what analysts think:

考慮購買KSS股票?以下是分析師的看法:

big

Read This Next:

Read This Next:

  • How To Earn $500 A Month From Marvell Technology Stock Ahead Of Q3 Earnings
  • 如何在邁威爾科技股票的Q3盈利發佈之前每個月賺取500美元

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論